当前位置:首页 - 行情中心 - 和元生物(688238) - 财务分析 - 现金流量表

和元生物

(688238)

  

流通市值:51.74亿  总市值:52.38亿
流通股本:6.41亿   总股本:6.49亿

现金流量表

报告期2025-06-302025-03-312024-12-312024-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金107,711,534.4942,360,963.7241,887,804.09166,602,196.16
  收到的税费返还--86,538,182.74-
  收到其他与经营活动有关的现金6,092,665.152,729,681.8942,181,986.3736,522,608.58
  经营活动现金流入小计113,804,199.6445,090,645.59370,607,973.2203,124,804.74
  购买商品、接受劳务支付的现金74,993,780.6540,242,328.54146,412,837.34112,927,530.44
  支付给职工以及为职工支付的现金97,783,019.3451,358,995.5208,389,699.34160,101,267
  支付的各项税费5,524,246.522,310,337.776,772,710.344,544,986.02
  支付其他与经营活动有关的现金24,002,770.7212,592,665.3370,101,204.4857,400,993.11
  经营活动现金流出小计202,303,817.23106,504,327.14431,676,451.5334,974,776.57
  经营活动产生的现金流量净额-88,499,617.59-61,413,681.55-61,068,478.3-131,849,971.83
二、投资活动产生的现金流量:
  收回投资收到的现金207,783,792.1490,000,000160,000,00020,000,000
  取得投资收益收到的现金680,175.51527,816.32824,149.85178,815.72
  处置固定资产、无形资产和其他长期资产收回的现金净额1,201,00053,0002,6702,550
  收到的其他与投资活动有关的现金--18,600,00018,600,000
  投资活动现金流入小计209,664,967.6590,580,816.32179,426,819.8538,781,365.72
  购建固定资产、无形资产和其他长期资产支付的现金90,939,935.7271,235,980.13167,457,233.05140,142,225.97
  投资支付的现金200,000,00080,000,000190,000,000100,000,000
  取得子公司及其他营业单位支付的现金116,922.06-283,077.94--
  支付其他与投资活动有关的现金--31,000,00031,000,000
  投资活动现金流出小计291,056,857.78150,952,902.19388,457,233.05271,142,225.97
  投资活动产生的现金流量净额-81,391,890.13-60,372,085.87-209,030,413.2-232,360,860.25
三、筹资活动产生的现金流量:
  吸收投资收到的现金--3,704,316-
  取得借款收到的现金200,000,000180,000,00090,000,00090,000,000
  筹资活动现金流入小计200,000,000180,000,00093,704,31690,000,000
  偿还债务支付的现金78,717,00077,483,50031,184,00029,950,500
  分配股利、利润或偿付利息支付的现金3,713,506.141,643,863.136,374,929.094,681,156.24
  支付其他与筹资活动有关的现金100,137,977.1658,488,697.353,936,368.183,799,568.93
  筹资活动现金流出小计182,568,483.3137,616,060.4841,495,297.2738,431,225.17
  筹资活动产生的现金流量净额17,431,516.742,383,939.5252,209,018.7351,568,774.83
四、汇率变动对现金及现金等价物的影响-23,479.12-5,811.58-202,675.37-27,425.61
五、现金及现金等价物净增加额-152,483,470.14-79,407,639.48-218,092,548.14-312,669,482.86
  加:期初现金及现金等价物余额434,894,251.83434,894,251.83652,986,799.97652,986,799.97
  期末现金及现金等价物余额282,410,781.69355,486,612.35434,894,251.83340,317,317.11
补充资料:
  净利润-104,481,169.78--322,182,350.33-
  资产减值准备509,253.14-55,507,906.49-
  固定资产和投资性房地产折旧45,066,475-78,592,321.65-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧45,066,475-78,592,321.65-
  无形资产摊销1,013,491.86-1,967,244.35-
  长期待摊费用摊销1,360,266.78-6,748,124.79-
  处置固定资产、无形资产和其他长期资产的损失879,106.69--5,900,892.14-
  公允价值变动损失-84,032.41--259,112.69-
  财务费用3,735,988.14-7,657,469.67-
  投资损失306,068.54--3,577.44-
  递延所得税1,636,905.43-13,263,529.11-
  其中:递延所得税资产减少1,667,041.85-18,070,454.15-
    递延所得税负债增加-30,136.42--4,806,925.04-
  存货的减少-3,677,137.3--2,002,935.57-
  经营性应收项目的减少-20,158,514.13-42,545,097.56-
  经营性应付项目的增加-15,834,876.89-54,754,787.03-
  其他--4,021,097.27-
  现金的期末余额282,410,781.69-434,894,251.83-
  减:现金的期初余额434,894,251.83-652,986,799.97-
  现金及现金等价物的净增加额-152,483,470.14--218,092,548.14-
公告日期2025-08-192025-04-242025-04-182024-10-24
审计意见(境内)标准无保留意见
TOP↑